Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ: APGE )

40.91 +0.04 (+0.10%)
Streaming Delayed Price Updated: 1:25 PM EDT, Aug 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
From NewAmsterdam Pharma N.V.
Via GlobeNewswire
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Misses EPS for Q1 2024
APGE stock results show that Apogee Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Earnings Superstars: 3 Stocks Primed to Outperform This Quarter
Discover how Nvidia, Apogee Therapeutics and JD.com stand out as earnings outperformers in their respective sectors. 
Via InvestorPlace
Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
APGE Stock Earnings: Apogee Therapeutics Beats EPS for Q4 2023
APGE stock results show that Apogee Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
From Apogee Therapeutics, LLC
Via GlobeNewswire
Crude Oil Down 1%; Dave Shares Jump After Q4 Results
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday. The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nasdaq Down 250 Points; ISM Services PMI Falls In February
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded down 0.64% to 38,741.00 while the NASDAQ fell 1.64% to 15,942.27. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Atopic Dermatitis-Focused Apogee Therapeutics Stock Trading Higher On Tuesday?
Apogee Therapeutics unveils promising Phase 1 data for APG777, a lead candidate for atopic dermatitis treatment. Interim results show sustained biomarker inhibition and favorable safety profile. Phase... 
Via Benzinga
NIO Reports Upbeat Earnings, Joins Dave, V2X, Riskified And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Dips Over 100 Points; Target Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.33% to 38,861.95 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
IPO Stock Apogee Shifts Higher On Solid Phase 1 Outcome
IPO stock Apogee eyed new highs Tuesday after its developmental inflammation treatment beat trial study objectives. 
Via Investor's Business Daily
Topics Initial Public Offering
Exposures Securities Market
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
From Apogee Therapeutics, LLC
Via GlobeNewswire
IPO watch 2024: Which new stocks will hit the market?
Expectations are high for the 2024 IPO market, with Reddit, Databricks, and Shein debuts anticipated, hinting at a substantial influx of new public companies. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Apogee Therapeutics, LLC
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.